Rogers Corporation Common Stock (ROG)
Stock · NYSE · Industrials
$133.39as of 10/16/2026
Price chart
ROG Signal Track Record
How signals performed across all stocks →What ROG's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | +2.0% | 63% | September 30, 2026 |
| Bollinger Band Breakout | 27 | +0.2% | 52% | September 22, 2026 |
| Bollinger Band Breakdown | 22 | -3.5% | 41% | July 29, 2026 |
| 200-Day Moving Average TouchActive now | 10 | -0.3% | 50% | August 22, 2025 |
| Any 20-session window (baseline) | +0.5% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ROG
Rogers Corporation designs, develops, manufactures, and sells engineered materials and components in the United States, other Americas, China, other Asia Pacific countries, Germany, Europe, the Middle East, and Africa. It operates in two Advanced Electronics Solutions (AES), Elastomeric Material Solutions (EMS) segments. The AES segment offers circuit materials, ceramic substrate materials, busbars, and cooling solut…
- Sector
- Industrials
- Industry
- Major Chemicals
- Employees
- 3,000
- Website
- www.rogerscorp.com/
Fundamentals
- 1-day range
- $133.04$137.01
- Market cap
- $2.39B
- P/E (trailing)
- 77.01
- P/E (forward)
- 29.31
- EPS (trailing)
- $1.74
- Dividend yield
- —
- Beta
- 0.44
- Avg. volume
- 241.8K
- Ex-dividend date
- January 9, 1992
How Rogers Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Rogers Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- ROGRogers Corporation Common Stock$133.37▼ 3.20%Market cap $2.39BP/E 77.01$75.14$169
- MTXMinerals Technologies Inc. Common Stock$62.99▼ 1.19%Market cap $2.34BP/E —$53.94$84.34
- CCChemours Company (The) Common Stock$12.74▼ 1.32%Market cap $2.27BP/E —$10.44$28.67
- PCTTUPureCycle Technologies Inc. Unit$3.5▲ 0.00%Market cap $2.21BP/E —$3.09$15.49
- OLNOlin Corporation Common Stock$15.65▲ 0.64%Market cap $2.14BP/E —$14.64$30.46
- NGVTIngevity Corporation Common Stock$69.82▼ 1.02%Market cap $2.66BP/E 44.55$45.85$79.29
- KWRQuaker Houghton Common Stock$156.96▼ 1.00%Market cap $2.88BP/E 28.06$112.18$183.01
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ROG Rogers Corporation Common Stock | $2.39B | 77.01 | $133.37 | ▼ 3.20% | $75.14$169 |
| MTX Minerals Technologies Inc. Common Stock | $2.34B | — | $62.99 | ▼ 1.19% | $53.94$84.34 |
| CC Chemours Company (The) Common Stock | $2.27B | — | $12.74 | ▼ 1.32% | $10.44$28.67 |
| PCTTU PureCycle Technologies Inc. Unit | $2.21B | — | $3.5 | ▲ 0.00% | $3.09$15.49 |
| OLN Olin Corporation Common Stock | $2.14B | — | $15.65 | ▲ 0.64% | $14.64$30.46 |
| NGVT Ingevity Corporation Common Stock | $2.66B | 44.55 | $69.82 | ▼ 1.02% | $45.85$79.29 |
| KWR Quaker Houghton Common Stock | $2.88B | 28.06 | $156.96 | ▼ 1.00% | $112.18$183.01 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Rogers Targets $1.5B Sales by 2030 on AI Data Center, Battery GrowthYahoo · 10/3/2026
- Rogers Consensus Price Target Increased by 11.54% to $197.20Fintel · 10/3/2026
- B. Riley Securities Maintains Buy on Rogers, Raises Price Target to $225benzinga · 10/1/2026
- Rogers Corp. (ROG) Moves 10.7% Higher: Will This Strength Last?Yahoo · 10/1/2026
- B. Riley Securities Maintains Buy on Rogers, Raises Price Target to $225Benzinga · 10/1/2026
- Freedom Capital Markets Maintains Buy on Rogers, Raises Price Target to $185Benzinga · 10/1/2026
- Roche presents new data at EURETINA, highlighting Vabysmo’s real-world effectiveness and safety across major retinal conditionsYahoo · 10/1/2026
- Roche’s giredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of MedicineYahoo · 10/1/2026
- Rogers Corporation (ROG) Analyst/Investor Day - SlideshowSeekingAlpha · 10/1/2026
Insider Activity
Insider Actions →- Russell Laura · September 5, 2026 · Tax Withholding31 @ $127.82
- Reeder Raymond Sean · August 14, 2026 · Tax Withholding15 @ $142.91
- El-Haj Ali Omar · July 12, 2026 · Tax Withholding8.9K @ $137.52
- El-Haj Ali Omar · May 19, 2026 · Grant24.8K
- Megan Faust · May 6, 2026 · Grant1.4K
- Woon Keat Moh · May 6, 2026 · Grant1.4K
- Lauzon Armand F Jr · May 6, 2026 · Grant1.4K
- COPE BRETT ALAN · May 6, 2026 · Grant1.4K
- Roby Anne K · May 6, 2026 · Grant1.4K
- Starkloff Eric Howard · May 6, 2026 · Grant1.4K
- Berger Larry L · May 6, 2026 · Grant1.4K
- Donna Costello · May 6, 2026 · Grant1.4K
- Jeffrey J. Owens · May 6, 2026 · Grant1.4K
- Larabee Brian Keith · May 1, 2026 · Sale830 @ $135.91
- Peter C. Wallace · April 30, 2026 · Sale1.4K @ $132.63
Institutional Ownership
March 31, 2026
- Total shares held
- 15.21M
- Total value held
- $1.60B
- Institutional holders
- 249
- Unknown3.31M
- Unknown1.52M
- Unknown798.2K
- Unknown720.8K
- Unknown705.0K
- Unknown584.3K
- Unknown475.0K
- Unknown468.4K
- Unknown423.8K
- Unknown321.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Roche presents new Phase III data and FDA approval
Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.
Roche presents new Phase III data and FDA approval. Roche reported new one-year Phase III data for vamikibart in treating uveitic macular edema, a condition causing vision loss. Additionally, the FDA approved Tecentriq for adjuvant treatment of stage III colon cancer. These developments reflect ongoing progress in the company's clinical pipeline and regulatory approvals.